Heart Attack
Also known as: MI, Myocardial infarction, Non-Q-wave infarct, Infarction, Stroke
Methodology & AI Transparency ⓘ
Heart Attack Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is a heart attack? A heart attack, also called a myocardial infarction, is a type of heart disease .
- 2 Real-world patient consensus: Mapped to Heart & Cardiovascular Disease under ICD-10-CM I21.4 for Heart Attack clinical workups.
- 3 Typical cash cost range: Clinicians assessing Heart Attack focus on subendocardial perfusion deficits [Heart Attack I21.4] and targeted history.
- 4 Top reported side effects / signs: Key Heart & Vascular biomarkers for Heart Attack (I21.4): Apolipoprotein B (ApoB) [Heart Attack I21.4] & Left Ventricular Ejection in Heart Attack (I21.4: Fraction (LVEF)) (55% – 70% (I21.4)).
Ask our AI Specialists anything about Heart Attack
What Is Heart Attack?
What is a heart attack? A heart attack, also called a myocardial infarction, is a type of heart disease . It happens when blood flow to the heart suddenly becomes blocked. Without the blood coming in, the heart can't get oxygen. If not treated quickly, the heart muscle begins to die. But if you get quick treatment, you may be able to prevent or limit damage to the heart muscle. That's why it's important to know the symptoms of a heart attack and call 911 if you or someone else is having them. A heart attack is different than sudden cardiac arrest . During a heart attack, the heart usually doesn't suddenly stop beating.
Pathophysiology, Underlying Causes & Clinical Presentation
Heart Attack (I21.4) alters heart & vascular homeostasis through subendocardial perfusion deficits [Heart Attack I21.4]; Cross-referenced with NIH MeSH (Myocardial Infarction), clinical remission targets Left Ventricular Ejection in Heart Attack (I21.4: Fraction (LVEF)) within 55% – 70% (I21.4).
Common Symptoms & Clinical Signs
- • Smoking. Quit , or never start, smoking
- • High cholesterol and high blood pressure . Manage both with diet , exercise , and medicine
- • Presentation of Heart Attack (I21.4): palpitations, skipped beats, in Heart Attack (I21.4: or irregular resting)
- • Secondary Heart Attack clinical sign: unexplained lower-extremity ankle in Heart Attack (I21.4: edema or rapid)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Heart Attack Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | I21.4 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Heart & Cardiovascular Disease | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Apolipoprotein B (ApoB) [Heart Attack I21.4] | < 70 mg/dL (I21.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Left Ventricular Ejection in Heart Attack (I21.4: Fraction (LVEF)) | 55% – 70% (I21.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: NT-proBNP [Heart Attack I21.4] | < 100 pg/mL (I21.4) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Heart Attack
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Nitroglycerin Rectiv, Nitrostat • RxCUI 198040 | Nitrate Vasodilator | 94% | $0.0619 | $ 19.89 /mo |
| Nitroglycerin Lingual Nitroglycerin Lingual Generic • RxCUI 705129 | Nitrate Vasodilator | 83% | $0.4761 | $ 27.78 /mo |
| Nitrostat (Nitroglycerin) Nitrostat • RxCUI 198038 | Nitrate Vasodilator | 80% | $1.5506 | $ 8.56 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Heart Attack)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| GLP-1RA vs. Placebo: Which Works Better for Heart failure and mildly reduced or preserved ejection fraction? GLP-1RA reduce HF exacerbations and can play a role in reducing hospitalizations, improving patient's functional status, and significantly impacting the global healthcare burden of HF. International journal of cardiology • 2025-11-01 • Meta-Analysis | N = 4,474 | 99/100 | PMID 40623630 ↗ |
| New Insights on GLP-1 receptor agonists on heart and blood vessel outcomes in heart failure with: What a 4,043-Participant Study Found GLP-1 RAs may significantly lower the combined risk of mortality and hospitalization in patients with HFpEF. Clinical research in cardiology : official journal of the German Cardiac Society • 2026-09-15 • Meta-Analysis | N = 4,043 | 99/100 | PMID 40637782 ↗ |
| New Insights on Sildenafil for congenital heart diseases induced lung high blood pressure, a: What a 849-Participant Study Found Sildenafil is a well-tolerated treatment in congenital heart diseases induced lung high blood pressure, as it has proven its efficacy not only in lowering both PAP mean and systolic but also in reducing the ventilation time,... BMC pediatrics • 2023-07-20 • Meta-Analysis | N = 849 | 97/100 | PMID 37474896 ↗ |
| New Insights on Major outcomes in high-risk hypertensive patients randomized to: What a 9,048-Participant Study Found Thiazide-type diuretics are superior in preventing 1 or more major forms of CVD and are less expensive. JAMA • 2002-12-18 • Randomized Controlled Trial | N = 9,048 | 96/100 | PMID 12479763 ↗ |
| New Insights on Glucose levels predict hospitalization for congestive heart failure in patients: What a 25,620-Participant Study Found Fasting plasma glucose is an independent predictor of hospitalization for CHF in high-risk subjects. Circulation • 2007-03-20 • Randomized Controlled Trial | N = 25,620 | 96/100 | PMID 17339550 ↗ |
Heart Attack Patient Community & “People Like Me” Threads
Filter Heart Attack community threads and patient logs by age, biological sex, dosage, and treatment duration.